News & Media
March 3, 2025
XMS Capital Partners Expands Healthcare Investment Banking Expertise with Addition of Veteran Banker Rick Kimball
XMS Capital Partners LLC (“XMS”), a global, independent financial services firm focused on M&A, corporate advisory, and asset management services, is pleased to announce the addition of Richard (Rick) Kimball as a Managing Director. His appointment underscores XMS’s commitment to expanding its healthcare investment banking capabilities and delivering exceptional advisory services to clients.
January 27, 2025
XMS Capital Partners Enhances Private Capital Raising and Merchant Banking Capabilities with the Addition of Paul Glover as Managing Director
XMS Capital Partners, LLC (“XMS”), a global, independent financial services firm focused on providing M&A, corporate advisory, capital raising and asset management services, is pleased to announce the addition of Paul Glover as Managing Director.
September 13, 2024
XMS Capital Partners Serves as Exclusive Financial Advisor to Liquid Bottles on its Sale to Novvia Group
XMS Capital Partners, LLC (“XMS”) a global, independent financial services firm focused on providing M&A, corporate advisory and capital raising services, announced that it served as exclusive financial advisor to Liquid Bottles LLC (“Liquid Bottles” or the “Company”) on its sale to Novvia Group (“Novvia”), a global rigid container and life sciences packaging distributor.
July 23, 2024
XMS Capital Partners Serves as Exclusive Financial Advisor to Block Mining on its Sale to Riot Platforms
Riot Platforms, Inc. (NASDAQ: RIOT) ("Riot" or "the Company"), an industry leader in vertically integrated Bitcoin mining, is pleased to announce that it has acquired Block Mining, Inc. ("Block Mining"), a Kentucky-based vertically integrated Bitcoin miner, for total consideration at closing of $92.5 million.
July 8, 2024
XMS Capital Partners Expands UK Footprint with FinTech and Financial Services Focus
XMS Capital Partners LLC (“XMS”), a global, independent financial services firm focused on providing M&A, corporate advisory and asset management services, is pleased to announce the expansion of its UK business with a focus on FinTech and Financial Services.
July 1, 2024
XMS Capital Partners Serves as Exclusive Financial Advisor to StatRad on its Sale to I-MED
XMS Capital Partners, LLC (“XMS”), a global, independent financial services firm focused on providing M&A, corporate advisory and asset management services, announced that it served as financial advisor to StatRad LLC (“StatRad” or the “Company”) on its sale to I-MED, an Australia-based radiology provider.
January 24, 2024
XMS Expands Industrial Sector Coverage in Automotive and Packaging with Two Managing Director Hires
XMS Capital Partners LLC (“XMS”), a global, independent financial services firm focused on providing M&A, corporate advisory and asset management services, is pleased to announce the additions of Christopher Blake and Todd VanderMolen to the firm as Managing Directors.
Dec 15, 2023
XMS Capital Partners Serves as Exclusive Financial Advisor to Bush Brothers Provision Company on its Partnership with Heartwood Partners
XMS Capital Partners, LLC (“XMS”), a global, independent financial services firm focused on providing M&A, corporate advisory and asset management services, announced that it served as financial advisor to Bush Brothers Provision Co. (“Bush Brothers” or the “Company”) on its majority investment with Heartwood Partners IV, LP (“Heartwood”), a middle market private equity firm. The investment was completed on July 7, 2023.
Feb 23, 2023
XMS Advised Exact Sciences on its $573mm Debt Exchange Transaction and Private Placement of Convertible Senior Notes
Exact Sciences Corp. (Nasdaq: EXAS) (the "Company"), a leading provider of cancer screening and diagnostic tests, today announced that on February 23, 2023 it entered into a privately negotiated exchange and purchase agreement (the "Agreement") with a holder of certain of the Company's 0.3750% Convertible Senior Notes due 2027 (the "Existing 2027 Notes") and certain of its 0.3750% Convertible Senior Notes due 2028 (the "Existing 2028 Notes", and together with the "Existing 2027 Notes", the "Existing Notes").
August 2, 2022
XMS Advised Exact Sciences on the Sale of its Oncotype DX® GPS Prostate Cancer Business to Mdxhealth
MDxHealth SA (NASDAQ/Euronext: MDXH) ("mdxhealth" or the "Company"), a commercial-stage precision diagnostics company, today announced it has entered into an asset purchase agreement with Genomic Health, Inc., a subsidiary of Exact Sciences Corporation ("Exact Sciences"), to acquire the Oncotype DX® GPS (Genomic Prostate Score®) test from Exact Sciences along with most of its team of urology sales and marketing professionals.